BioSpace News Archive

Presentation and webcast to take place at 10 a.m. ET on January 14

IQVIA™, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, announced that Laboratoires Théa, the leading independent eye care group in Europe, has selected IQVIA Technologies’ Orchestrated Customer Engagement platform and the OneKey HCP/HCO reference database for deployment across more than 22 markets.

Impulse Dynamics, a company dedicated to helping healthcare providers improve the lives of people with heart failure, today announced the first patient in Brazil was treated with its innovative CCM® therapy delivered by the Optimizer® system.

PolarityTE, Inc. (Nasdaq: PTE) , a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H.C. Wainwright Virtual Bioconnect Conference on January 11, 2021. A webcast of the presentation will be available on January 11, 2021 beginning at 6:00 a.m. Eastern Time and can be accessed in the “News & Media/Events” section of PolarityTE’s website at www

CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space, announced today that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for its product CUREfilm Blue

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) a clinical stage biopharmaceutical company focused on Artificial Intelligence driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis and liver disease, announced today that management will participate in two virtual investor conferences in January.

Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company will present at the 13 th Annual Biotech Showcase Digital Event, January 11-15, 2021. Chief Executive Officer at ITI, Dr. Bill Hearl, will present a talk titled, “ITI-1000-A Novel Immunotherapy for GBM.” Dr. Hearl will discuss ITI’s investigational UNiversal Intracellular Targeted Expression (UNITE)

Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $100M. The PRV was granted to Rhythm by the U.S. Food and Drug Administration (FDA) with the approval of IMCIVREE™ (setmelanotide) for chronic w

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 12:40 p.m. Pacific Time. A live audio webcast of the presentatio

Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will participate in the H.C. Wainwright Virtual BioConnect 2021 Conference to be held January 11-14, 2021 and the LifeSci Advisors 10th Annual Corporate Access Event to be held January 6-14, 2021. The virtual LifeSci Advisors event presentation will be live at 1